Tech

MBFPhTI and GENERIUM signed a memorandum of cooperation

MBFPhTI and the Russian company GENERIUM have agreed to develop cooperation in biopharmaceuticals, biotechnology, and scientific research.

MBFITI and GENERIUM signed a memorandum of cooperation

The National Research Institute of Biopharmaceutics (MBFITI) and the Russian company "GENERIUM" signed a memorandum of cooperation in the field of biopharmaceutics and biotechnology.

The document provides for the development of scientific and practical cooperation, exchange of experience, and joint implementation of promising projects.

The memorandum was signed following a visit by MBFITI representatives to the Russian company "GENERIUM". During the trip, the Uzbek delegation got acquainted with the company's activities, its research and development potential, as well as the directions of development and production of biopharmaceutical products.

The parties discussed promising areas of further cooperation in the field of biopharmaceutics. Special attention was paid to the development and production of biological medicines, the application of modern biotechnologies, and the implementation of research results into practical activities.

Among the areas of cooperation, conducting analytical research and developing technological processes were also considered. A special emphasis was placed on the exchange of professional experience between specialists of the two organizations.

According to the agreements reached, the cooperation between MBFITI and "GENERIUM" will include support for research and development activities and joint work on promising projects in the field of biopharmaceutics and biotechnology.

Cookies on xabarchi

We use cookies to remember your language and theme, and to count how many people are reading right now — that count is anonymous, lasts only while your browser is open, and cannot be tied to you or to another visit. With your permission we also measure how the site is read: Microsoft Clarity, which records page views and on-page interactions, and our own count of returning readers. Nothing that recognises you across visits is measured until you accept.